Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Interchange of vaccine products
Clinical narrative: Rebound Covid-19; The patient received previously two doses of Pfizer vaccine as primary schedule; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Rebound Covid-19) and INTERCHANGE OF VACCINE PRODUCTS (The patient received previously two doses of Pfizer vaccine as primary schedule) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer/Biontech (1st dose on right arm at 12:00 pm) on 31-Mar-2021 and Pfizer/Biontech (2nd dose on right arm at 12:00 pm) on 14-Apr-2021. Past adverse reactions to the above products included No adverse event with Pfizer/Biontech and Pfizer/Biontech. Concurrent medical conditions included Rheumatoid arthritis and Drug allergy (unspecified drug).   On 28-Aug-2021 at 12:00 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-May-2022 at 7:00 PM, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Rebound Covid-19) and INTERCHANGE OF VACCINE PRODUCTS (The patient received previously two doses of Pfizer vaccine as primary schedule). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 20-May-2022 to 24-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Rebound Covid-19) and INTERCHANGE OF VACCINE PRODUCTS (The patient received previously two doses of Pfizer vaccine as primary schedule) outcome was unknown.            No concomitant medication was reported. On 01-Jun-2022 at 10:00 PM, the patient had rebound covid. On an unknown date, patient was recovering from the event of rebound covid. Device date was reported as 03-Jun-2022. Company comment: This spontaneous case of concerns a 50-year-old female patient, with no relevant medical history, who experienced the unexpected, non-serious of COVID-19. The event was reported with no onset date. As per source document, she received Paxlovid as COVID-19 treatment 3 days after the last dose of mRNA-1273 vaccine. Interchange of vaccine products case, as it is reported that the patient received previously two doses of Pfizer vaccine as primary schedule and two doses of mRNA-1273 vaccine as the third and fourth doses. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case of concerns a 50-year-old female patient, with no relevant medical history, who experienced the unexpected, non-serious  of COVID-19. The event was reported with no onset date. As per source document, she received Paxlovid as COVID-19 treatment 3 days after the last dose of mRNA-1273 vaccine. Interchange of vaccine products case, as it is reported that the patient received previously two doses of Pfizer vaccine as primary schedule and two doses of mRNA-1273 vaccine as the third and fourth doses. The benefit-risk relationship of mRNA-1273 is not affected by this report.